WASHINGTON: Many Indian drug makers will soon have to bear higher costs for sale of products in American markets, as the US Food and Drug Administration (FDA) is hiking the fees for generic drug makers by up to 48 per cent from October.
India is the second largest drug exporter to the US, according to the US health regulator.
Indian drug makers mostly specialise in manufacturing of generic versions of innovative drugs at a fraction of cost after their patent expiry and are estimated to command a 10 per cent share in the $30-billion US generic drug market.
0 comments:
Post a Comment